Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,466,673
  • Shares Outstanding, K 79,194
  • Annual Sales, $ 77,470 K
  • Annual Income, $ -178,840 K
  • 60-Month Beta 1.59
  • Price/Sales 18.72
  • Price/Cash Flow N/A
  • Price/Book 4.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.67
  • Number of Estimates 6
  • High Estimate -0.53
  • Low Estimate -0.77
  • Prior Year -0.54
  • Growth Rate Est. (year over year) -24.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.50 +4.51%
on 07/02/19
19.06 -4.04%
on 07/11/19
+0.64 (+3.63%)
since 06/14/19
3-Month
16.20 +12.90%
on 05/01/19
24.56 -25.53%
on 04/29/19
-5.61 (-23.47%)
since 04/15/19
52-Week
16.20 +12.90%
on 05/01/19
41.55 -55.98%
on 08/08/18
-20.46 (-52.80%)
since 07/13/18

Most Recent Stories

More News
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Heron Therapeutics, Inc. ("Heron" or "the Company") (NASDAQ: HRTX) for violations...

HRTX : 18.29 (-1.24%)
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Heron Therapeutics, Inc. ("Heron") or the ("Company") (NASDAQ:HRTX) of the August 5, 2019 deadline to seek the role of...

HRTX : 18.29 (-1.24%)
Hecla Mining Company (HL), Community Health Systems, Inc. (CYH) & Heron Therapeutics, Inc. (HRTX) - Bronstein, Gewirtz & Grossman, LLC Class Action Update

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints...

CYH : 2.40 (-2.04%)
HL : 1.73 (unch)
HRTX : 18.29 (-1.24%)
Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. - HRTX

Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Heron Therapeutics, Inc. (NASDAQ: HRTX) from October 31, 2018 through April 30, 2019, inclusive...

HRTX : 18.29 (-1.24%)
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HRTX, EQT, DBD and INS

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

DBD : 9.44 (+2.61%)
EQT : 15.62 (-1.26%)
HRTX : 18.29 (-1.24%)
INS : 38.15 (unch)
Pawar Law Group Reminds Investors of August 5 Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. - HRTX

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Heron Therapeutics, Inc. (NASDAQ: HRTX) from October 31, 2018 through April 30, 2019,...

HRTX : 18.29 (-1.24%)
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Heron Therapeutics, Inc. ("Heron") or the ("Company") (NASDAQ:HRTX) of the August 5, 2019 deadline to seek the role of...

HRTX : 18.29 (-1.24%)
Cytomx Therapeut has the Best Relative Performance in the Biotechnology Industry (CTMX , HRTX , FGEN , SGEN , LJPC )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

CTMX : 11.79 (-0.25%)
FGEN : 46.43 (+1.82%)
HRTX : 18.29 (-1.24%)
Heron Therapeuti Shares Down 22.7% Since SmarTrend's Sell Call (HRTX)

SmarTrend identified a Downtrend for Heron Therapeuti (NASDAQ:HRTX) on March 15th, 2019 at $23.97. In approximately 4 months, Heron Therapeuti has returned 22.72% as of today's recent price of $18.52....

HRTX : 18.29 (-1.24%)
HRTX Class Action Deadline: Bernstein Liebhard LLP Reminds Investors That Approximately 3 Weeks Remain to Make a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Heron Therapeutics, Inc. -- HRTX

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announced that approximately 3 weeks remain to make a motion to serve as lead plaintiff in a class action pending against Heron...

HRTX : 18.29 (-1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade HRTX with:

Business Summary

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting....

See More

Key Turning Points

2nd Resistance Point 19.17
1st Resistance Point 18.73
Last Price 18.29
1st Support Level 18.04
2nd Support Level 17.80

See More

52-Week High 41.55
Fibonacci 61.8% 31.87
Fibonacci 50% 28.88
Fibonacci 38.2% 25.88
Last Price 18.29
52-Week Low 16.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar